

Stanley R Hamilton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6382092/publications.pdf>

Version: 2024-02-01

34
papers

2,338
citations

394421

19
h-index

414414

32
g-index

34
all docs

34
docs citations

34
times ranked

4501
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18654-18659.	7.1	496
2	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
3	Increased Risk of Colorectal Cancer Development Among Patients With Serrated Polyps. Gastroenterology, 2016, 150, 895-902.e5.	1.3	184
4	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology, 2020, 38, 3883-3894.	1.6	168
5	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nature Reviews Clinical Oncology, 2015, 12, 197-212.	27.6	162
6	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. Journal of the National Cancer Institute, 2020, 112, 1021-1029.	6.3	138
7	Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial. Journal of Molecular Diagnostics, 2017, 19, 313-327.	2.8	115
8	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut, 2016, 65, 977-989.	12.1	111
9	Molecular Biomarkers for the Evaluation of Colorectal Cancer. Journal of Molecular Diagnostics, 2017, 19, 187-225.	2.8	108
10	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer, 2016, 114, 1352-1361.	6.4	81
11	Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget, 2016, 7, 11434-11449.	1.8	74
12	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget, 2017, 8, 39268-39279.	1.8	69
13	Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clinical Cancer Research, 2018, 24, 521-531.	7.0	64
14	Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Modern Pathology, 2008, 21, S23-S30.	5.5	55
15	Clinical and Molecular Characteristics of Post-Colonoscopy Colorectal Cancer: A Population-based Study. Gastroenterology, 2016, 151, 870-878.e3.	1.3	53
16	Effect of Capiwasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor. JAMA Oncology, 2021, 7, 271.	7.1	49
17	Assessment of <i>BRAF</i> V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Molecular Cancer Therapeutics, 2015, 14, 2887-2895.	4.1	38
18	Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.. Journal of Clinical Oncology, 2018, 36, 101-101.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	1.6	26
20	2010 Staging System for Colon and Rectal Carcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 1513-1517.	1.5	14
21	Characterizing the Killer Colorectal Carcinomas. <i>Cancer Cell</i> , 2018, 33, 7-9.	16.8	14
22	<i>MIP</i> haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. <i>Journal of Pathology</i> , 2017, 241, 67-79.	4.5	13
23	State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials—A Multidisciplinary Approach. <i>Journal of Clinical Oncology</i> , 2020, 38, 1633-1640.	1.6	12
24	Differential expression of microRNA-320a, -145, and -192 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum. <i>American Journal of Surgery</i> , 2014, 207, 717-722.	1.8	11
25	Regulation of <i>AURKC</i> expression by CpG island methylation in human cancer cells. <i>Tumor Biology</i> , 2015, 36, 8147-8158.	1.8	9
26	Phase II Study of Taselisib in <i>PIK3CA</i> -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424.	3.0	9
27	Molecular pathology. <i>Molecular Oncology</i> , 2012, 6, 177-181.	4.6	8
28	Expression of p27Kip1 and bcl-2, cigarette smoking, and colorectal cancer risk. <i>Biomarkers</i> , 2000, 5, 225-234.	1.9	3
29	Phase I/II first-in-human CAR T-cell targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1130-TPS1130.	1.6	3
30	Status of Testing for High-Level Microsatellite Instability/Deficient Mismatch Repair in Colorectal Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e173574.	7.1	2
31	Proliferation, apoptosis and their regulatory protein expression in colorectal adenomas and serrated lesions. <i>PLoS ONE</i> , 2021, 16, e0258878.	2.5	1
32	Phase II study of vismodegib in patients with <i>SMO</i> or <i>PTCH1</i> mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T. <i>Journal of Clinical Oncology</i> , 2022, 40, 3010-3010.	1.6	1
33	Malignant Tumors of the Colon. , 0, , 1669-1716.		0
34	Comparison of AYA versus non-AYA ovarian cancer genomic landscape in NCI-MATCH trial. <i>Journal of Clinical Oncology</i> , 2022, 40, e17617-e17617.	1.6	0